A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy

BMC Cancer

Table 2 Murine anti-human PSA IgG2a titers in the serum of vaccinated human FcεRIα transgenic mice

Titers 14 days after initial immunization
Mouse #	PSA + anti-PSA IgE	PSA + anti-PSA IgG1	PSA	Buffer
1	0	0	0	0
2	0	0	0	0
3	200	0	0	0
4	0	0	0	0
5	0	0	50	0
6	0	0	0	0
7	0	0	0	0
8	100	0	0	0
Median	0	0	0	0
Titers 13 days after booster (28 days after initial immunization)
Mouse #	PSA + anti-PSA IgE	PSA + anti-PSA IgG1	PSA	Buffer
1	0	0	1,600	0
2	200	0	50	0
3	200	50	0	0
4	800	0	0	0
5	200	50	400	0
6	400	50	0	0
7	100	50	50	0
8	100	50	50	0
Median	200	50	50	0

Data shown are combined from two separate experiments (n = 4) with a total of 8 animals per group. Sera were serially diluted 2-fold starting at 1:50. Titer was determined as the highest dilution from which a positive signal was obtained.

ISSN: 1471-2407